Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Pharmacovigilance Update Still Causing Concern

This article was originally published in The Pink Sheet Daily

Executive Summary

The European pharma industry understands the need to tighten EU pharmacovigilance rules, but increased powers for a new advisory and assessment body could signal trouble ahead.

You may also be interested in...

EMA Birth Control Safety Review Shows PRAC’s Clout, Concern About Newer Products

The Pharmacovigilance Risk Assessment Committee is assessing whether use of third- and fourth-generation combined oral contraceptives should be limited to women who cannot take other birth control pills; this is the ninth group of drugs PRAC has been asked to review.

FDA Puts Several Drugs On Its “Nice” List; EMA Decides One Is “Naughty”

NPS Pharmaceuticals, GSK, Roche and Cangene receive early holiday gifts as FDA goes on an approval spree. But EMA bears more bad news for Merck’s Tredaptive.

Europeans Tighten Drug Safety By Monitoring Active Ingredients

EMA publishes a list of active ingredients that must be monitored by European Union countries as part of efforts there to improve interstate communication and drug safety.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts